Please provide your email address to receive an email when new articles are posted on . Wainua has received regulatory approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct ...

– EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo – CARLSBAD, ...

Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.

Since 1995 I have had the interesting experience of working as a neurologist in a large state prison whose primary mission is to provide medical care to inmates. A large proportion of my practice ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among adults with type 2 diabetes, those reporting ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

Patisiran continued to demonstrate benefit in hATTR with polyneuropathy at 5 years. Measures of disability, polyneuropathy, and quality of life showed modest changes. This is the longest study of an ...

Hereditary transthyretin amyloidosis (hATTR) is a rare inherited disorder that gets worse over time. It often affects the nerves, heart, liver, and kidneys, but it can also affect other organs.

Amvuttra is a subcutaneously-administered RNAi therapeutic designed to block the production of wild-type and mutant transthyretin protein. The Food and Drug Administration (FDA) has approved Amvuttra ...

BOSTON — In a small study of patients labeled as having fibromyalgia, almost half actually had small-fiber polyneuropathy (SFPN), a potentially treatable condition. Therefore, it is important that ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI. CIDP ...